A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

  • STATUS
    Not Recruiting
  • End date
    May 14, 2024
  • participants needed
    638
  • sponsor
    Bristol-Myers Squibb
Updated on 17 February 2021
sunitinib
systemic therapy
carcinoma
vegf
growth factor
cabozantinib
nivolumab
ipilimumab
curative surgery
metastatic renal cell carcinoma

Summary

The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Details
Condition Renal Cell Carcinoma
Treatment Ipilimumab, Nivolumab, Sunitinib, Cabozantinib
Clinical Study IdentifierNCT03141177
SponsorBristol-Myers Squibb
Last Modified on17 February 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note